Pipeline

Athos Therapeutics is a clinical stage company with assets in Inflammatory Bowel Diseases, lupus, and cancer. Athos is also pursuing discovery efforts against a range of validated and novel drug targets for patients with different autoimmune diseases.

Disease Application

Small Molecule

Discovery

Preclinical

Phase 1

Phase 2

Lead Programs

IBD

ATH-063

IBD/Fibrosis, AD, SSc

ATH-391

Obesity

ATH-091

Sjogren’s Syndrome, Cardiovascular Risk, Parkinson’s Disease

ATH-501

Early Stage Programs

IBD, RA

ATH-301

Fibrosis, COPD

ATH-350

IPF, Asthma, EoE

ATH-601

Ankylosing Spondylitis, Behcet’s Syndrome

ATH-702

IBD: Inflammatory Bowel Diseases

SLE: Systemic Lupus Erythematosus

T1D: Type 1 Diabetes

AD: Atopic Dermatitis

EoE: Eosinophilic Esophagitis